CapsoVision (CV) Q2 2025 earnings summary

Executive summary

• Advanced imaging and AI technologies drive capsule endoscopy solutions for GI tract diagnostics, with CapsoCam Plus as the main revenue source and CapsoCam Colon in development targeting FDA clearance in 2026.

• Revenue growth is driven by increased CapsoCam Plus sales, expansion into pediatric and telehealth markets, and ongoing R&D for new indications and AI features.

• CapsoCam Plus, FDA-cleared for small bowel visualization, is commercially available in the U.S. and internationally, with unique 360-degree imaging and high procedural completion rates.

• Operations are funded primarily through equity sales and, most recently, an IPO in July 2025, raising $23.4 million in net proceeds.

• Development pipeline includes AI-powered modules, colon capsule, and future screening for pancreas and esophageal varices.

Financial highlights

• Q2 2025 revenue was $3.3 million, up 17% year-over-year, driven by increased CapsoCam Plus sales.

• Gross margin for Q2 2025 was 55%; six-month gross margin was 54%.

• Operating expenses were $6.5 million for Q2 2025, down from $6.9 million in Q2 2024, mainly due to lower clinical trial costs.

• Net loss for Q2 2025 was $4.6 million, or $2.02 per share, improved from $5.3 million, or $2.58 per share, in Q2 2024.

• Cash at June 30, 2025 was $1.1 million, with IPO proceeds of $23.4 million received in July.

Outlook and guidance

• Second half 2025 revenue expected to exceed first half, with Q4 historically strongest.

• Anticipates continued market share gains, AI module FDA submission by late September/early October, and regulatory clearance for colon capsule with AI by second half 2026.

• Negative net income for 2025 projected at $20–22 million; cash burn rate about $2 million per month.

• Net proceeds from the IPO and existing cash are not expected to fund operations for the next 12 months; additional capital will be required.

• Expansion into new GI indications and AI-driven product enhancements are planned, subject to funding and regulatory milestones.